Inflammatory Cytokine and Neuropeptide Study in Patients With Herpes Zoster
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- serum level of inflammatory cytokine changes during 3 time period
Study Overview
Brief Summary
Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with herpes zoster.
Detailed Description
Sudden and electrick shooting sensation of face is an important clinical feature of herpes zoster. The severe and excruciating nature of pain intensity associated with herpes zoster can impair the physical and psychosocial well-being of the patient, however, pathophysiologic mechanism of herpes zoster still remains unclear.
Recentrly, there have been a few studies suggesting biomarker levels in the blood and CSF level, however, further study is required to elucidate the action mechanism.
Up to 90% of patients can achieve pain reduction using medical therapy alone. However, 10% -15% of herpes zoster cases demonstrate a minimal response to medication with various side effects. Radiofrequency thermocoagulation (RFT) of the trigeminal ganglion is an alternative treatment option for patients who are poor candidates for microvascular decompression or show serious side effects to medication. Recent study revealed that RFT of the trigeminal ganglion resulted in Barrow Neurological Institute (BNI) pain scale I or II in 71.7% of patients, with a median time to recurrence of 36 months.
Although patients experience significant pain relief after RFT, it is uncertain whether inflammatory cytokine and neurocytokine (CGRP, substance P, VIP) are reduced.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 20 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •patients with NRS more than 4
- •patients who failed medical treatment
- •patients showing severe adverse reaction with medication
Exclusion Criteria
- •Patients showing allergic reaction to local anesthetics
- •Patients with coagulation abnormality
Arms & Interventions
herpes zoster (acute) patients with intervention
Patients with herpes zoster receiving 2 times of nerve block
Intervention: Herpes zoszter (acute)with inter vention (Procedure)
patients with chronic herpes zoster receiving 2 times of nerve block
Patients with herpes zoster receiving 2 times of nerve block
Intervention: Herpes zoszter (acute)with inter vention (Procedure)
Outcomes
Primary Outcomes
serum level of inflammatory cytokine changes during 3 time period
Time Frame: Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
inflammatory cytokine including Tumor necrosis factor-alpha, Interleukin-6 changes during 3 time period Higher score means worse outcome
serum level of neurotransmitter changes during 3 time period
Time Frame: Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
neurotransmitter including Calcitonene gene related peptide, substance P, vasoactive intestitinal polypeptide changes during 3 time period Higher score means worse outcome
Secondary Outcomes
- Changes of numerical rating scale changes during 3 time period(Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation)
Investigators
Ji Hee Hong
Professor
Keimyung University Dongsan Medical Center